Business LineBusiness NewsCOVID-19

Wipro partners with Hyderabad Startup to transform vaccine safety assessment

On Wednesday, the tech giant Wipro said it has partnered with Hyderabad-based startup Transcell Oncologics to enhance vaccine safety assessment by deploying artificial intelligence. 

The statement suggests the partnership will enable Wipro’s HOLMES platform to combine its advanced AI power with Transcell’s stem cell technology to refurbish the safety of global vaccine immunization programs. 

With the amalgamation of AI and human stem cells, a solution will be created capable of predicting the adverse neurovirulent impact caused by vaccination on a vaccinated individual. The solution is highly adaptable and can be integrated into any existing workflow, including quality control tests in vaccine production, batch-wise release, and related housekeeping safety evaluation assays. 

This new partnership aims to produce a series of solutions that will provide viable choices to animal-based testing to determine the safety and efficacy of drugs and consumer goods involving cosmetics. 

The global head of engineering and R&D at Wipro, Harmeet Chauhan said-  “Enhancing neurovirulence safety assessment through AI, without the need for animal-based testing, is a huge step forward. This innovative technology has allowed us to embrace a more humane approach and simultaneously raised the effectiveness of vaccine testing. Our partnership with Transcell Oncologics will bring the best of AI and stem cell technology to users, enabling customers to subdue their go to market timeline and expedite the safe vaccination program”. 

Talking about Wipro HOLMES, it has offerings that apply AI for drug repurposing and Messenger Ribonucleic Acid (mRNA) based platform for biodefense. 

Meanwhile, the CEO of Transcell Subhadra Dravida said- “This exciting alliance merges the biotechnology capabilities of Transcell Oncologics’s Transtoxbio vertical with the advanced AI capabilities of Wipro HOLMES to derive holistic insights from a human surrogate in vitro platforms employed. This breakthrough process will open up new possibilities in the life sciences industry and accelerate innovation that is vital to saving lives”. 

Moreover, the solution by Wipro-Transcell HOLmes received an award at the Chem TECH BioPharma World.IE Conference, a biopharma gathering attended by multiple CXOs, the government’s National Biopharma Mission, and Venture advisors.

Content Protection by

Back to top button

Adblock Detected